Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfiredoxin: a potential therapeutic agent?

Victoria J Findlay1, Haim Tapiero, Danyelle M Townsend

  • 1Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC 29425, USA.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring Copaiba and Andiroba Oils: A Comprehensive Review of Composition, Physicochemical Properties and Pharmacological Activities in Advanced Delivery Systems.

Pharmaceutics·2026
Same author

Small-Molecule Targeting of VDAC Disrupts Mitochondrial Bioenergetics and Suppresses Melanoma Cell Survival and Migration.

Cells·2026
Same author

Small molecule inhibition of voltage dependent anion channel 1 reroutes mitochondrial metabolite flux.

Molecules and cells·2026
Same author

Corrigendum "Adaptations in glutathione-based redox protein signaling pathways and alcohol drinking across species" [Biomed. Pharmacother. 180 (2024) 117514].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Senescence at the crossroads of postpartum remodeling and tumorigenesis.

Nature aging·2026
Same author

Making deep immunophenotyping accessible: the successful application of a guided 23-parameter mouse immunophenotyping panel package provided through a shared resource.

Frontiers in immunology·2026
Same journal

Corrigendum to 'A new perspective on targeting pulmonary arterial hypertension: Programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)' [Biomed. Pharmacother. 181 (2024) 117706].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

From DNA-encoded library (DEL) screening to in vivo validation: LILRB4 (ILT3)-targeted small molecules reprograms myeloid immune suppression.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Wnt activation during epileptogenesis prevents pathological immature dentate granule cell morphological changes in animal models of unilateral and bilateral temporal lobe epilepsy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Sulfiredoxin (Srx) is a novel antioxidant protein that regulates peroxiredoxins and deglutathionylation. This protein impacts cell signaling and may play a role in various disease states.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Background:

  • Antioxidants like peroxiredoxin (Prx) are crucial for maintaining cellular homeostasis.
  • Sulfiredoxin (Srx) is a recently discovered antioxidant protein involved in redox signaling.
  • Srx regulates Prx function by reducing cysteine sulfinic acid, preventing protein degradation.

Purpose of the Study:

  • To review the role of Sulfiredoxin (Srx) as a novel antioxidant.
  • To focus on Srx's potential involvement in regulating glutathionylation/deglutathionylation pathways.
  • To highlight the implications of these pathways in various disease states.

Main Methods:

  • Literature review of existing studies on Srx and its functions.
  • Analysis of Srx's catalytic activity in reducing oxidative modifications.

Related Experiment Videos

  • Examination of Srx's role in deglutathionylation of proteins in vitro and in vivo.

    • Main Results:

    • Srx catalyzes the reduction of cysteine sulfinic acid in Prx, impacting downstream signaling.
    • Srx reduces glutathionylation, a post-translational modification implicated in diseases like Parkinson's.
    • Srx-dependent deglutathionylation is observed in response to oxidative stress.

    Conclusions:

    • Srx functions as a key regulator of redox balance and cellular signaling.
    • The deglutathionylation activity of Srx suggests a significant role in mitigating oxidative stress-related pathologies.
    • Further research into Srx pathways could reveal new therapeutic targets for diseases involving oxidative damage.